Applied DNA Sciences (NASDAQ:APDN) is up 9% premarket on the heels of an announcement related to the development of linear-DNA form of COVID-19 vaccine candidates with development partner Takis Biotech.
The results of linear-DNA dose-response trials are expected in this month.
The companies’ development program utilizes the
plasmid-based DNA templates to determine baseline results in preclinical
animal models.
Th results are anticipated to reduce risk of antibiotic resistance and genomic integration, and speed of production.
If found to be as efficacious as the plasmid-based
templates, the company and Takis will engage a third-party to conduct
toxicology studies to generate necessary data for potential human
clinical trials of the linear-DNA vaccines.
https://seekingalpha.com/news/3581095-applied-dna-updates-on-covidminus-19-vaccine-program
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.